BAJAJ BROKING

Notification close image
No new Notification messages
card image
Cash UR Drive Marketing IPO is Open!
Apply for the Cash UR Drive Marketing IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Dr. Reddy’s Laboratories Q1 Results FY26: Revenue Rises 11% YoY, Net Profit at ₹141.78 Crore

Dr. Reddy’s Laboratories Q1 Results FY26: Revenue Rises 11% YoY, Net Profit at ₹141.78 Crore

Synopsis:

Dr. Reddy’s reported Q1 FY26 revenue of ₹8545.2 crore and net profit of ₹141.78 crore, reflecting 11% YoY growth. Robust branded markets and nicotine product sales contributed to results, although US price erosion and higher SG&A expenses tempered overall margins.

Key Highlights / Quick Insights

  • Revenue from operations: ₹8545.2 Cr (↑ 11% YoY)

  • Profit before tax (PBT): ₹190.47 Cr (↑ 1% YoY)

  • Profit after tax (PAT): ₹141.78 Cr (↑ 2% YoY)

  • Total income: ₹8862.4 Cr

  • EBITDA: ₹227.84 Cr (26.7% of revenue)

  • EPS (Diluted): ₹17.02

  • R&D expenses: ₹6.24 Cr (7.3% of revenue)

  • SG&A expenses: ₹256.47 Cr

  • Gross margin: 56.9%

DR. REDDY S LABORATORIES

Trade

1220.6-49.70 (-3.91 %)

Updated - 01 August 2025
1259.00day high
DAY HIGH
1213.70day low
DAY LOW
2525210
VOLUME (BSE)

Quarterly Performance: Dr. Reddy’s Q1 FY25-26

Dr. Reddy’s Laboratories delivered stable performance in Q1 FY26, supported by strength in branded generics and Nicotine Replacement Therapy (NRT) portfolio. A snapshot of performance metrics is as follows:

Particulars

Q1 FY26 (₹ Cr)

Q1 FY25 (₹ Cr)

Change (%)

Revenue from Operations

8545.2

7672.7

11%

Total Income

8862.4

7883.3

12%

EBITDA

2278.4

2159.9

5%

Profit Before Tax

1904.7

1882.1

1%

Profit After Tax

1417.8

1392.0

2%

EPS (Diluted)

17.02

16.69

-

Segment Highlights

Segment

Revenue (₹ Cr)

Segment Result / Gross Profit (₹ Cr)

Global Generics

7562.0

4608.6

Pharmaceutical Services & APIs (PSAI)

970.9

108.2

Others

165.1

145.9

Inter-segment Elimination

(152.8)

-

Total

8545.2

4862.7

Dr. Reddy’s segment-wise performance in Q1 FY26 showed healthy momentum across its core verticals:

  • Global Generics remained the largest contributor, generating ₹7562.0 crore in revenue and ₹4608.6 crore in gross profit. Growth was supported by strong traction in branded markets and the acquired NRT portfolio.

  • Pharmaceutical Services and Active Ingredients (PSAI) delivered revenue of ₹970.9 crore, with a segment profit of ₹108.2 crore, backed by new API launches and service-led growth.

  • Other Segments, which include proprietary and emerging initiatives, contributed ₹165.1 crore in revenue and ₹145.9 crore in profit.

Sector Expectations for Dr. Reddy’s Q1 FY26

The pharmaceutical sector anticipated stable to moderate growth amid global headwinds. Dr. Reddy’s delivered in line with these expectations, aided by its diversified portfolio and strategic acquisitions. The NRT acquisition, new product launches in Europe and India, and sustained R&D investments underscore its long-term growth approach.

Management Commentary

Commenting on the results, Co-Chairman & MD, G V Prasad said: 

"We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market. We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development." 

For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

Source - Q1 FY25-26 Quarterly Results Uploaded on BSE dated 23 July 2025

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|